ESC Heart Failure (Aug 2024)

Long‐term prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation

  • Kenichi Ishizu,
  • Shinichi Shirai,
  • Akihiro Isotani,
  • Masaomi Hayashi,
  • Hiroyuki Tabata,
  • Nobuhisa Ohno,
  • Shinichi Kakumoto,
  • Kenji Ando,
  • Fumiaki Yashima,
  • Norio Tada,
  • Masahiro Yamawaki,
  • Toru Naganuma,
  • Futoshi Yamanaka,
  • Hiroshi Ueno,
  • Minoru Tabata,
  • Kazuki Mizutani,
  • Kensuke Takagi,
  • Yusuke Watanabe,
  • Masanori Yamamoto,
  • Kentaro Hayashida,
  • OCEAN‐TAVI Investigators

DOI
https://doi.org/10.1002/ehf2.14773
Journal volume & issue
Vol. 11, no. 4
pp. 2159 – 2171

Abstract

Read online

Abstract Aims A considerable proportion of candidates for transcatheter aortic valve implantation (TAVI) have underlying heart failure (HF) with preserved ejection fraction (HFpEF), which can be challenging for diagnosis because significant valvular heart disease should be excluded before diagnosing HFpEF. This study investigated the long‐term prognostic value of the pre‐procedural H2FPEF score in patients with preserved ejection fraction (EF) undergoing TAVI. Methods and results Patients who underwent TAVI between October 2013 and May 2017 were enrolled from the Optimized CathEter vAlvular iNtervention–Transcatheter Aortic Valve Implantation Japanese multicentre registry. After excluding 914 patients, 1674 patients with preserved EF ≥ 50% (median age: 85 years, 72% female) were selected for calculation of the H2FPEF score and were dichotomized into two groups: the low H2FPEF score [0–5 points; n = 1399 (83.6%)] group and the high H2FPEF score [6–9 points; n = 275 (16.4%)] group. Patients with high H2FPEF scores were associated with a higher prevalence of New York Heart Association Functional Class III/IV (59.3% vs. 43.7%, P < 0.001), diabetes (24.4% vs. 18.5%, P = 0.03), and paradoxical low‐flow, low‐gradient aortic stenosis (15.9% vs. 6.2%, P < 0.001). These patients showed worse prognoses than those with low H2FPEF scores regarding the cumulative 2 year all‐cause mortality (26.3% vs. 15.5%, log‐rank P < 0.001), cardiovascular mortality (10.5% vs. 5.4%, log‐rank P < 0.001), HF hospitalization (16.2% vs. 6.7%, log‐rank P < 0.001), and the composite endpoint of cardiovascular mortality and HF hospitalization (23.8% vs. 10.8%, log‐rank P < 0.001). After adjustment for several confounders, the high H2FPEF scores were independently associated with increased risk for all‐cause mortality [adjusted hazard ratio (HR), 1.48; 95% confidence interval (CI), 1.09–2.00; P = 0.011] and for the composite endpoint of cardiovascular mortality and HF hospitalization (adjusted HR, 1.95; 95% CI, 1.38–2.74; P < 0.001). Subgroup analysis confirmed the excess risk of high H2FPEF scores relative to low H2FPEF scores for the composite endpoint of cardiovascular mortality and HF hospitalization increased with a lower Society of Thoracic Surgeons (STS) score (STS score <8%: adjusted HR, 2.40; 95% CI, 1.50–3.85; P < 0.001; STS score ≥8%: adjusted HR, 1.34; 95% CI, 0.79–2.28; P = 0.28; Pinteraction = 0.030). Conclusions The H2FPEF score is useful for predicting long‐term adverse outcomes after TAVI, including all‐cause mortality, cardiovascular mortality, and HF hospitalization for patients with preserved EF. More aggressive interventions targeting HFpEF in addition to the TAVI procedure might be relevant in patients with high H2FPEF scores, particularly in those with a lower surgical risk.

Keywords